The TLR7 agonists tested to date in phase I trials include GS-9620, RO7020531 and TQ-A3334 were all shown to be safe and well tolerated in hepatitis B patients and healthy volunteers [40,41,42,43]. Here, TLR7 is linked to hepatitis B virus infection.